Filing Details
- Accession Number:
- 0001213900-21-004482
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-26 19:30:34
- Reporting Period:
- 2021-01-22
- Accepted Time:
- 2021-01-26 19:30:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1553643 | Relmada Therapeutics Inc. | RLMD | Pharmaceutical Preparations (2834) | 455401931 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1658544 | Edward Paul Kelly | C/O Relmada Therapeutics, Inc. 880 Third Avenue, 12Th Floor New York NY 10022 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-22 | 4,085 | $3.24 | 151,380 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-22 | 1,800 | $3,543.00 | 149,580 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-22 | 300 | $36.18 | 149,280 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-25 | 1,300 | $35.27 | 147,980 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-26 | 685 | $35.16 | 147,295 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to purchase common stock | Disposition | 2021-01-22 | 4,085 | $0.00 | 3,400 | $3.24 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
86,415 | 2017-10-20 | 2027-10-20 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.
- The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- Sales prices range from $35.04 to $35.98 per share, inclusive.
- Sales prices range from $36.06 to $36.37 per share, inclusive.
- Sales prices range from $35.00 to $35.51 per share, inclusive.
- Sales prices range from $35.00 to $35.75 per share, inclusive.
- The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.
- Not applicable.